On March 28, 2018 OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary immunotherapy cancer vaccine technology and targeted cancer therapies, is reported that Phase 2 clinical trial of ProscaVax for early-stage prostate cancer to be hosted at a teaching hospital of Harvard University Medical School in Boston, MA (Press release, Oncbiomune, MAR 28, 2018, http://oncbiomune.com/2018/03/28/oncbiomune-returns-protocol-to-scientific-review-committee-overseeing-phase-2-prostate-cancer-clinical-trial/ [SID1234525384]). The Company earlier this week completed and returned the revised study protocol based upon comments from the Scientific Review Committee (SRC) providing oversight on the trial.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As announced last Thursday, March 22, 2018, the SRC had minimal comments regarding the protocol.
"We didn’t foresee any issues with getting the revisions completed and back to the SRC ahead of their request by the end of the month," commented Dr. Jonathan Head, Chief Executive Officer at OncBioMune. "The suggestions from the experts on the committee were greatly appreciated and easily dovetailed with the greater body of work. Again, I’m pleased to continue to move towards the start of this very important trial."

ProscaVax is OncBioMune’s lead immunotherapy candidate consisting of a combination of prostate cancer associated prostate specific antigen (PSA) with the biological adjuvants interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF). The Company has successfully completed a Phase 1a clinical trial of ProscaVax in hormone-naïve and hormone-independent recurrent prostate cancer patients with increasing PSA. The planned Phase 2 study at the teaching hospital of Harvard University Medical School is being designed to treat prostate cancer patients in the "active surveillance" group, representing the first-ever clinical study of a therapeutic vaccine for patients in this group to the Company’s knowledge. Active surveillance is a disease management option for patients with localized prostate cancer that elect to work with their doctor to monitor the disease for progression before taking any intervention measures, such as surgery or radiotherapy.

Sign up for OncBioMune email alerts at: View Source